Basic Stats
| CIK | 1208261 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Immune Pharmaceuticals Inc.
SEC Filings (Chronological Order)
This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.
| April 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 13, 2021 IMMUNE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Nevada 001-36602 86-3202343 (State or other jurisdiction of incorporation) (Commissi |
|
| April 13, 2021 |
Exhibit 1 |
|
| April 13, 2021 |
Exhibit 2 |
|
| April 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 12, 2021 IMMUNE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or other jurisdiction of incorporation) (Commis |
|
| August 9, 2019 |
INAN / InterNatural Pharmaceuticals, Inc. / Hughes Eric Olan - FORM13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| March 8, 2019 |
Press release dated March 7, 2019 Exhibit 10.2 Immune Pharmaceuticals Announces Leadership Transition FORT LEE, NJ (March 7, 2019) - Immune Pharmaceuticals, Inc. (OTC PINK: IMNPQ) (“Immune” or the “Company”), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced that Gary Rabin has been appointed as President and interim Chief Executive Officer (CEO) a |
|
| March 8, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 17, 2019 IMMUNE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or other jurisdiction of incorporation) (Com |
|
| March 8, 2019 |
Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (“Agreement”) is entered into as of March 7, 2019, by and between Gary H. Rabin (“Rabin”), and Immune Pharmaceuticals Inc ("Company"). Company desires to engage Rabin as President and Interim Chief Executive Officerto provide certain services to Company as more particularly set forth in Exhibit A attached hereto and made a part hereof (th |
|
| February 14, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 8, 2019 Immune Pharmaceuticals Inc. |
|
| February 14, 2019 |
NOTICE OF DEFAULT AND NOTICE OF SALE OF COLLATERAL Exhibit 99.1 NOTICE OF DEFAULT AND NOTICE OF SALE OF COLLATERAL Reference is made to the Securities Purchase Agreement (“Agreement”) dated October 9, 2018, between Immune Pharmaceuticals Inc., a Delaware corporation (“Company”) and Discover Growth Fund, LLC (“Investor”), and the Senior Secured Redeemable Convertible Debenture (“Debenture”) issued by Company to Investor pursuant to the Agreement. P |
|
| February 7, 2019 |
Immune Pharmaceuticals Inc. Up to 123,333,333 Shares of common stock Filed Pursuant to Rule 424(b)(4) Registration No. 333-228512 PRELIMINARY PROSPECTUS Immune Pharmaceuticals Inc. Up to 123,333,333 Shares of common stock This prospectus relates to the resale or other disposition by the selling stockholder (the “Selling Stockholder”) identified in this prospectus and its transferees of up to 123,333,333 shares of our common stock, par value $0.0001 per share. All o |
|
| January 17, 2019 |
IMNP / Immune Pharmaceuticals Inc. S-1/A As filed with the Securities and Exchange Commission on January 17, 2019 Registration No. |
|
| January 17, 2019 |
Exhibit 10.42 FIRST AMENDMENT AGREEMENT This First Amendment Agreement (this “Amendment”) is made as of January 15, 2019 (the “Effective Date”) by and between Immune Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Discover Growth Fund, LLC. (“Discover”). RECITALS WHEREAS, the Company and Discover entered into a Securities Purchase Agreement dated October 9, 2018 (the “Securities |
|
| December 19, 2018 |
IMNP / Immune Pharmaceuticals Inc. S-1/A As filed with the Securities and Exchange Commission on December 19, 2018 Registration No. |
|
| December 19, 2018 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT OF THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF IMMUNE PHARMACEUTICALS INC. Pursuant to Section 242 of the General Corporation Law of the State of Delaware, Immune Pharmaceuticals Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), does hereby certify as follows: 1. The name of the Corporation is |
|
| December 19, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 19, 2018 Immune Pharmaceuticals Inc. |
|
| December 6, 2018 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 5, 2018 IMMUNE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or other jurisdiction of incorporation) (Commi |
|
| December 6, 2018 |
Exhibit 99.1 Immune Pharmaceuticals Announces Adjournment of Special Meeting of Stockholders Meeting adjourned in order to gather additional votes Fort Lee, NJ (December 6, 2018) – Immune Pharmaceuticals, Inc. (OTCQB; IMNP) (“Immune” or the “Company”) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced today that its |
|
| December 6, 2018 |
Press Release, dated December 6, 2018 Exhibit 99.1 Immune Pharmaceuticals Announces Adjournment of Special Meeting of Stockholders Meeting adjourned in order to gather additional votes Fort Lee, NJ (December 6, 2018) – Immune Pharmaceuticals, Inc. (OTCQB; IMNP) (“Immune” or the “Company”) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced today that its |
|
| December 6, 2018 |
IMNP / Immune Pharmaceuticals Inc. FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 5, 2018 IMMUNE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or other jurisdiction of incorporation) (Commi |
|
| November 28, 2018 |
Exhibit 99.1 Immune Pharmaceuticals and Vector Therapeutics Sign Option Agreement for Worldwide Ceplene® Rights Immune Receives $500,000 for Option; If Exercised, Total Deal Value Could Exceed $17.5 Million FORT LEE, NJ and NEW YORK, NY (November 27, 2018) – Immune Pharmaceuticals, Inc. (OTCQB: IMNP) (“Immune”), a biopharmaceutical company developing novel therapeutic agents for the treatment of i |
|
| November 28, 2018 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 23, 2018 IMMUNE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or other jurisdiction of incorporation) (Comm |
|
| November 26, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 26, 2018 IMMUNE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or other jurisdiction of incorporation) (Comm |
|
| November 21, 2018 |
Powers of Attorney (included on signature page of the Registration Statement) As filed with the Securities and Exchange Commission on November 21, 2018 Registration No. |
|
| November 21, 2018 |
Exhibit 10.32 NOMINEE AGREEMENT dated March 27, 2018 made by and among CYTOVIA INTERNATIONAL LLC and NOVENTIA PHARMA SRL regarding the the European market authorizations of Ceplene® and other products of Cytovia Table of Contents 1. INTERPRETATION 1 2. ENGAGEMENT 3 3. PAYMENT 3 4. CONFIDENTIALITY 4 5. WARRANTIES 5 6. LIABILITY AND INSURANCE 5 7. COMPLIANCE WITH THE LAW 5 8. FORCE MAJEURE 7 9. ASSI |
|
| November 21, 2018 |
Third Amended and Restated Certificate of Incorporation, as amended. Exhibit 3.1 THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF EPICEPT CORPORATION EpiCept Corporation, a Delaware corporation (the “Corporation”), does hereby certify that: FIRST: The name of the Corporation is “EpiCept Corporation.” The Corporation was originally incorporated under the name “American Pharma-Liedtke, Inc.” by the filing of its original Certificate of Incorporation with th |
|
| November 14, 2018 |
IMNP / Immune Pharmaceuticals Inc. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-36602 Immune Pharmaceuticals Inc. (Exact name of registra |
|
| November 8, 2018 |
IMNP / Immune Pharmaceuticals Inc. DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State |
|
| October 29, 2018 |
IMNP / Immune Pharmaceuticals Inc. PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| October 22, 2018 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 18, 2018 IMMUNE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or other jurisdiction of incorporation) (Commi |
|
| October 10, 2018 |
Exhibit 10.3 Form of Warrant NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE “SECURITIES ACT”), AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE |
|
| October 10, 2018 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (“Agreement”) is made and entered into on October 9, 2018 (“Effective Date”), by and between Immune Pharmaceuticals, Inc., a Delaware corporation (“Company”), and the investor whose name appears on the signature page hereto (“Investor”). Recitals A. The parties desire that, upon the terms and subject to the conditions he |
|
| October 10, 2018 |
Exhibit 10.4 Form of Investor Note PROMISSORY NOTE Initial Principal Amount: $3,000,000.00 Issuance Date: October 9, 2018 FOR VALUE RECEIVED, the borrower whose name appears on the signature page hereto (“Borrower”), promises to pay to the order of Immune Pharmaceuticals Inc., a Delaware corporation (“Lender”), the Initial Principal Amount, together with interest thereon, as follows: 1. Agreement. |
|
| October 10, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 9, 2018 IMMUNE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or other jurisdiction of incorporation) (Commi |
|
| October 10, 2018 |
Exhibit 99.1 Immune Pharmaceuticals Announces $5 Million Financing Company to launch bertilimumab partnering process in the current quarter FORT LEE, NJ (October 9, 2018) - Immune Pharmaceuticals, Inc. (OTCQB: IMNP) (“Immune” or the “Company”), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced today that it has ent |
|
| October 10, 2018 |
Exhibit 10.2 Form of Debenture NEITHER THE ISSUANCE NOR SALE OF THE SECURITIES REPRESENTED BY THIS INSTRUMENT NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATI |
|
| September 18, 2018 |
Exhibit 10.2 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE |
|
| September 18, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 12, 2018 IMMUNE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or other jurisdiction of incorporation) (Co |
|
| September 18, 2018 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of September 12, 2018, by and between Immune Pharmaceuticals Inc., a Delaware corporation, with its address at 550 Sylvan Avenue, Suite 101, Englewood Cliffs, NJ 07632 (the “Company”), and POWER UP LENDING GROUP LTD., a Virginia corporation, with its address at 111 Great Neck Road, Suite 216, |
|
| September 10, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 10, 2018 IMMUNE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or other jurisdiction of incorporation) (Co |
|
| August 28, 2018 |
Exhibit 10.3 First Amendment to Employment Terms Whereas, Anthony Fiorino, MD, PhD (“Executive” or “You”) is currently employed by Immune Pharmaceuticals Inc. (the “Company;” collectively, the “Parties”) as the Company’s Chief Medical Officer and Chief Operating Officer; and Whereas, the Parties are bound by a Letter Agreement dated August 14, 2017, specifying the terms and conditions of Executive |
|
| August 28, 2018 |
Exhibit 10.1 August 28, 2018 Elliot Maza 150 Columbus Avenue, Apt 6D New York, NY 10023 Re: Termination of Employment Dear Elliot, This letter summarizes the discussions between you and Immune Pharmaceuticals, Inc. (together with its subsidiaries, the “Company”), regarding the terms and conditions of the termination of your employment by the Company and your resignation as a member of the Company’ |
|
| August 28, 2018 |
Exhibit 10.2 General Release of Claims I, Elliot Maza (the “Employee”), in consideration of and subject to the performance by Immune Pharmaceuticals, Inc. (together with its subsidiaries, the “Corporation”), of its obligations under the Employment Agreement dated as of November 1, 2017, as modified by a letter agreement dated the date hereof (as so amended, the “Agreement”), do hereby release and |
|
| August 28, 2018 |
8-K 1 tv5019178k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 28, 2018 IMMUNE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or other jurisdiction |
|
| August 14, 2018 |
IMNP / Immune Pharmaceuticals Inc. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-36602 Immune Pharmaceuticals Inc. (Exact name of registrant as |
|
| July 26, 2018 |
Exhibit 99.1 Immune Pharmaceuticals Receives Nasdaq Delisting Determination; Eligible to trade Over-the-Counter July 26, 2018 ENGLEWOOD CLIFFS, NJ (July 26, 2018) - Immune Pharmaceuticals, Inc. (Nasdaq: IMNP) (“Immune” or the “Company”), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today announced that it has received w |
|
| July 26, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 24, 2018 IMMUNE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or other jurisdiction of incorporation) (Commissi |
|
| July 17, 2018 |
IMNP / Immune Pharmaceuticals Inc. DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| July 17, 2018 |
IMNP / Immune Pharmaceuticals Inc. DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State |
|
| June 29, 2018 |
IMNP / Immune Pharmaceuticals Inc. PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ☐ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| June 8, 2018 |
8-K 1 tv4960248k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 4, 2018 IMMUNE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or other jurisdicti |
|
| June 8, 2018 |
Exhibit 99.1 Immune Pharmaceuticals Announces Receipt of Nasdaq Listing Determination - Company to Request Hearing - Englewood Cliffs, NJ (June 8, 2018) – Immune Pharmaceuticals, Inc. (Nasdaq: IMNP) (“Immune” or the “Company”), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced today that it received a letter (the " |
|
| May 15, 2018 |
IMNP / Immune Pharmaceuticals Inc. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-36602 Immune Pharmaceuticals Inc. (Exact name of registrant a |
|
| May 14, 2018 |
8-K 1 tv4941048k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 14, 2018 IMMUNE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or other jurisdicti |
|
| May 14, 2018 |
Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIS |
|
| May 14, 2018 |
EX-10.1 2 tv494104ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 14, 2018, between Immune Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”) |
|
| May 7, 2018 |
8-K 1 tv4932878k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 1, 2018 IMMUNE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or other jurisdictio |
|
| May 7, 2018 |
Immune Pharmaceuticals Provides Update on Plans for Oncology Subsidiary, Cytovia, Inc., Exhibit 99.1 Immune Pharmaceuticals Provides Update on Plans for Oncology Subsidiary, Cytovia, Inc., Englewood Cliffs, NJ (May 7, 2018) – Immune Pharmaceuticals, Inc. (NASDAQ: IMNP) (“Immune” or the “Company”), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today announced that the Company’s Board of Directors (the “Board |
|
| April 2, 2018 |
Exhibit 21.1 Subsidiaries of Immune Pharmaceuticals Inc. The following are the subsidiaries of Immune Pharmaceuticals Inc.: Name Jurisdiction of Incorporation Immune Pharmaceuticals USA Corp. Delaware Immune Pharmaceuticals Ltd. Israel Maxim Pharmaceuticals, Inc. Delaware Cytovia, Inc. Delaware Immune Oncology Pharmaceuticals Inc. Delaware |
|
| April 2, 2018 |
IMNP / Immune Pharmaceuticals Inc. FORM 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2017 ¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 001-36602 Immune Pharmaceutical |
|
| February 28, 2018 |
Immune Pharmaceuticals Announces Outcome of Annual Meeting of Stockholders Exhibit 99.1 Immune Pharmaceuticals Announces Outcome of Annual Meeting of Stockholders Englewood Cliffs, NJ (February 27, 2018) ? Immune Pharmaceuticals, Inc. (NASDAQ; IMNP) (?Immune? or the ?Company?) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced today that Proposal 4 - Ratification of the Reverse Stock Split |
|
| February 28, 2018 |
8-K 1 tv4873058k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 23, 2018 IMMUNE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or other juris |
|
| February 20, 2018 |
8-K 1 tv4865048k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 15, 2018 IMMUNE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or other juris |
|
| February 20, 2018 |
EX-99.1 2 tv486504ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Immune Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders and Provides Business Update · 5 of 6 proposals pass with shareholder approval · Meeting adjourned solely with respect to Proposal 4 – Ratification of the Reverse Stock Split · Company outlines key corporate and clinical milestones for 2018 Englewood Cliffs, NJ (Feb |
|
| February 14, 2018 |
INAN / InterNatural Pharmaceuticals, Inc. / Skidmore Brian - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Immune Pharmaceuticals Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45254C200 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| February 12, 2018 |
Exhibit 99.1 www.immunepharma.com NASDAQ: IMNP BIO CEO and Investor Conference Elliot Maza ? Chief Executive Officer February 12, 2018 Forward Looking Statements This presentation and oral statements made by representatives of the Company may contain projections or other forward - looking statements regarding future events or the future financial performance of the Company. Actual events or result |
|
| February 12, 2018 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 12, 2018 IMMUNE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or other jurisdiction of incorporation) (Com |
|
| February 8, 2018 |
Immune Pharmaceuticals to be Delisted from Nasdaq Stockholm Exhibit 99.1 Immune Pharmaceuticals to be Delisted from Nasdaq Stockholm Englewood Cliffs, NJ- February 8, 2018 ? Immune Pharmaceuticals Inc. (NASDAQ First North: IMNP) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases (the ?Company?) announced today that the Disciplinary Board of Nasdaq Stockholm has decided to delist the Co |
|
| February 8, 2018 |
Financial Statements and Exhibits, Other Events 8-K 1 tv4852858k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 7, 2018 IMMUNE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or other jurisd |
|
| January 26, 2018 |
IMNP / Immune Pharmaceuticals Inc. DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| January 26, 2018 |
Exhibit 99.1 Immune Pharmaceuticals Announces Adjournment of Annual Meeting Annual Meeting to Resume Thursday, February 15, 2018 Englewood Cliffs, NJ - January 26, 2018 ? Immune Pharmaceuticals Inc. (NASDAQ: IMNP), a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced today that it adjourned its Annual Meeting of Stock |
|
| January 26, 2018 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 25, 2018 IMMUNE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or other jurisdiction of incorporation) (Comm |
|
| January 9, 2018 |
Exhibit 99.1 CONFIDENTIAL Not to be Used or Distributed Without Immune?s Permission IMMUNE PHARMACEUTICALS (NASDAQ: IMNP) Elliot Maza, President & CEO January 10, 2018 2 This presentation and oral statements made by representatives of the Company may contain forward - looking statements regarding future events or the future financial performance of the Company . These statements are based on our c |
|
| January 9, 2018 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 9, 2018 IMMUNE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or other jurisdiction of incorporation) (Commi |
|
| December 19, 2017 |
IMNP / Immune Pharmaceuticals Inc. DEF 14A DEF 14A 1 tv481518def14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as p |
|
| December 14, 2017 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant 8-K/A 1 tv4814108ka.htm FORM 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 14, 2017 IMMUNE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-184143 |
|
| December 14, 2017 |
Letter from BDO USA, LLP, dated December 14, 2017 EX-16.1 2 tv481410ex16-1.htm EXHIBIT 16.1 Exhibit 16.1 Tel: 212-371-4446 Fax: 212-371-9374 www.bdo.com 622 Third Ave, Suite 3100 New York, NY 10017 December 14, 2017 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 We have been furnished with a copy of the response to Item 4.01 of Form 8-K for the event that occurred on December 7, 2017, to be filed by our former client, |
|
| December 14, 2017 |
Changes in Registrant's Certifying Accountant 8-K 1 tv4813688k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 7, 2017 IMMUNE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or other jurisd |
|
| December 8, 2017 |
IMNP / Immune Pharmaceuticals Inc. PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: x Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| December 6, 2017 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 8-K 1 tv4808228k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 1, 2017 IMMUNE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or other jurisd |
|
| December 4, 2017 |
8-K 1 tv4807048k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 29, 2017 IMMUNE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or other juris |
|
| December 4, 2017 |
EX-10.1 2 tv480704ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 EMPLOYMENT AGREEMENT (“Agreement”), as of December 1, 2017, by and between Immune Pharmaceuticals, Inc., a Delaware corporation with offices at 550 Sylvan Avenue, Englewood Cliffs, NJ 07632 (the “Corporation”) and Elliot Maza, an individual (“Executive”). WITNESSETH WHEREAS, Executive served as the Interim Chief Executive Officer of the Corpor |
|
| November 27, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 20, 2017 IMMUNE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or other jurisdiction of incorporation) (Comm |
|
| November 17, 2017 |
EX-99.1 2 tv479884ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Immune Pharmaceuticals Inc. and Subsidiaries Pro forma Condensed Consolidated Balance Sheets ($ in thousands, except share and per share amounts) As Reported Pro forma Adjustments Pro forma September 30, 2017 (Unaudited) Sale of Series E Convertible Preferred Stock and Warrants (Unaudited) September 30, 2017 (Unaudited) ASSETS Current Assets C |
|
| November 17, 2017 |
Financial Statements and Exhibits, Other Events 8-K 1 tv4798848k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 17, 2017 IMMUNE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or other jurisd |
|
| November 14, 2017 |
IMNP / Immune Pharmaceuticals Inc. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-36602 Immune Pharmaceuticals Inc. (Exact name of registra |
|
| October 25, 2017 |
Exhibit 3.1 Page 1 Delaware The First State I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF DESIGNATION OF “IMMUNE PHARMACEUTICALS INC.”, FILED IN THIS OFFICE ON THE NINETEENTH DAY OF OCTOBER, A.D. 2017, AT 4:35 O’CLOCK P.M. A FILED COPY OF THIS CERTIFICATE HAS BEEN FORWARDED TO THE KENT COUNTY RECO |
|
| October 25, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 19, 2017 IMMUNE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or other jurisdiction (Commission (IRS Employe |
|
| October 23, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 23, 2017 IMMUNE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or other jurisdiction of incorporation) (Comm |
|
| October 23, 2017 |
Immune Provides Additional Financial Information in Response to Nasdaq First North Stockholm Exhibit 99.2 Immune Provides Additional Financial Information in Response to Nasdaq First North Stockholm Englewood Cliffs, NJ ? October 23, 2017 - Immune Pharmaceuticals Inc. (the "Company?) announced today the public disclosure of certain information regarding its current financial position. As disclosed in the Company?s Quarterly Report on Form 10-Q filed with the United States Securities and E |
|
| October 23, 2017 |
Exhibit 99.1 October 23, 2017 IMMUNE PHARMACEUTICALS INC. ANNOUNCES CLOSING OF $18,000,000 PUBLIC OFFERING OF CONVERTIBLE PREFERRED STOCK AND WARRANTS ENGLEWOOD CLIFFS, N.J., (BUSINESS WIRE) – Immune Pharmaceuticals Inc. (“Immune”) (NASDAQ: IMNP) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today announced the closing o |
|
| October 20, 2017 |
424B4 1 t1702792-424b4.htm FINAL PROSPECTUS TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(4) Registration No. 333-220413 Immune Pharmaceuticals Inc. 18,000 Units consisting of Series E convertible preferred stock and warrants (and 35,352,000 shares of common stock underlying shares of Series E convertible preferred stock and warrants) We are offering 18,000 units, with each unit consisting of |
|
| October 19, 2017 |
S-1MEF 1 tv477286s1mef.htm S-1MEF As filed with the Securities and Exchange Commission on October 19, 2017 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IMMUNE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 2836 52-1841431 (State or other jurisdicti |
|
| October 18, 2017 |
As filed with the Securities and Exchange Commission on October 17, 2017 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on October 17, 2017 Registration No. |
|
| October 18, 2017 |
COMMON STOCK PURCHASE WARRANT IMMUNE PHARMACEUTICALS INC. Exhibit 10.84 COMMON STOCK PURCHASE WARRANT IMMUNE PHARMACEUTICALS INC. Warrant Shares: [ ] Initial Exercise Date: [ ], 2017 Warrant Number: [ ] Issue Date: [ ], 2017 CUSIP: [ ] ISIN: [ ] THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, Cede & Co. or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the condi |
|
| October 17, 2017 |
IMNP / Immune Pharmaceuticals Inc. ESP CORRESP 1 filename1.htm Maxim Group LLC 405 Lexington Ave New York, NY 10174 October 17, 2017 Via EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Immune Pharmaceuticals Inc. Registration Statement on Form S-1 (SEC File No. 333-220413) Ladies and Gentleman: In connection with the above referenced Registration State |
|
| October 17, 2017 |
IMNP / Immune Pharmaceuticals Inc. ESP CORRESP 1 filename1.htm Immune Pharmaceuticals Inc. 550 Sylvan Avenue Englewood Cliffs, NJ 07632 October 17, 2017 VIA EDGAR Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Immune Pharmaceuticals Inc. Registration Statement on Form S-1 File No. 333-220413 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules an |
|
| October 17, 2017 |
IMNP / Immune Pharmaceuticals Inc. ESP CORRESP 1 filename1.htm October 17, 2017 Securities and Exchange Commission Division of Corporation Finance United States Securities and Exchange Commission 100 F. Street, NE Washington, DC 20549 Attention: Mr. Chris Edwards and Ms. Suzanne Hayes Re: Immune Pharmaceuticals Inc. Amendment No. 2 to Registration Statement on Form S-1 Filed October 16, 2017 File No. 333-220413 Dear Mr. Edwards and Ms. |
|
| October 16, 2017 |
IMNP / Immune Pharmaceuticals Inc. ESP CORRESP 1 filename1.htm October 16, 2017 Securities and Exchange Commission Office of Healthcare & Insurance 100 F. Street, NE Washington, DC 20549 Attention: Mr. Chris Edwards and Ms. Suzanne Hayes Re: Immune Pharmaceuticals Inc. Amendment No. 1 to Registration Statement on Form S-1 Filed October 11, 2017 File No. 333-220413 Dear Mr. Edwards and Ms. Hayes: This letter sets forth the responses of |
|
| October 16, 2017 |
Exhibit 10.85 Immune Pharmaceuticals Inc. and VStock Transfer, LLC, as Warrant Agent Warrant Agency Agreement Dated as of October [ ], 2017 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of October [ ], 2017 (?Agreement?), between Immune Pharmaceuticals Inc., a Delaware corporation (the ?Company?), and VStock Transfer, LLC, a New York limited liability trust company (the ?Warrant Agen |
|
| October 16, 2017 |
As filed with the Securities and Exchange Commission on October 16, 2017 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on October 16, 2017 Registration No. |
|
| October 16, 2017 |
IMMUNE PHARMACEUTICALS INC. UNDERWRITING AGREEMENT Exhibit 1.1 IMMUNE PHARMACEUTICALS INC. UNDERWRITING AGREEMENT [ ], 2017 Maxim Group LLC 405 Lexington Avenue New York, New York 10174 As Representative of the Underwriters named on Schedule A hereto Ladies and Gentlemen: Immune Pharmaceuticals Inc., a Delaware corporation (the ?Company?), proposes, subject to the terms and conditions stated herein, to issue and sell to the underwriters named in S |
|
| October 16, 2017 |
COMMON STOCK PURCHASE WARRANT IMMUNE PHARMACEUTICALS INC. Exhibit 10.84 COMMON STOCK PURCHASE WARRANT IMMUNE PHARMACEUTICALS INC. Warrant Shares: [ ] Initial Exercise Date: [ ], 2017 Warrant Number: [ ] Issue Date: [ ], 2017 CUSIP: [ ] ISIN: [ ] THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, Cede & Co. or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the condi |
|
| October 16, 2017 |
Exhibit 3.10 IMMUNE PHARMACEUTICALS INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES E 8% CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW IMMUNE PHARMACEUTICALS INC., a Delaware corporation (the ?Corporation?), in accordance with the provisions of Section 103 of the Delaware General Corporation Law (the ?DGCL?) does hereby |
|
| October 11, 2017 |
IMMUNE PHARMACEUTICALS INC. UNDERWRITING AGREEMENT EX-1.1 2 t1702537ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 IMMUNE PHARMACEUTICALS INC. UNDERWRITING AGREEMENT [ ], 2017 Maxim Group LLC 405 Lexington Avenue New York, New York 10174 As Representative of the Underwriters named on Schedule A hereto Ladies and Gentlemen: Immune Pharmaceuticals Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue |
|
| October 11, 2017 |
IMNP / Immune Pharmaceuticals Inc. ESP October 11, 2017 Securities and Exchange Commission Office of Healthcare & Insurance 100 F. |
|
| October 11, 2017 |
COMMON STOCK PURCHASE WARRANT IMMUNE PHARMACEUTICALS INC. EX-10.84 5 t1702537ex10-84.htm EXHIBIT 10.84 Exhibit 10.84 COMMON STOCK PURCHASE WARRANT IMMUNE PHARMACEUTICALS INC. Warrant Shares: [ ] Initial Exercise Date: [ ], 2017 Warrant Number: [ ] Issue Date: [ ], 2017 CUSIP: [ ] ISIN: [ ] THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Cede & Co. or its assigns (the “Holder”) is entitled, upon the terms and subject |
|
| October 11, 2017 |
EX-10.85 6 t1702537ex10-85.htm EXHIBIT 10.85 Exhibit 10.85 Immune Pharmaceuticals Inc. and VStock Transfer, LLC, as Warrant Agent Warrant Agency Agreement Dated as of October [ ], 2017 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT, dated as of October [ ], 2017 (“Agreement”), between Immune Pharmaceuticals Inc., a Delaware corporation (the “Company”), and VStock Transfer, LLC, a New York limit |
|
| October 11, 2017 |
EX-3.10 3 t1702537ex3-10.htm EXHIBIT 3.10 Exhibit 3.10 IMMUNE PHARMACEUTICALS INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES E 8% CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW IMMUNE PHARMACEUTICALS INC., a Delaware corporation (the “Corporation”), in accordance with the provisions of Section 103 of the Delaware Genera |
|
| October 11, 2017 |
As filed with the Securities and Exchange Commission on October 11, 2017 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on October 11, 2017 Registration No. |
|
| October 3, 2017 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 v4763798k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 3, 2017 IMMUNE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or other jurisdic |
|
| October 3, 2017 |
Exhibit 99.1 IMMUNE PHARMACEUTICALS Rebuilding with Bertilimumab October 2017 2 This presentation and oral statements made by representatives of the Company may contain projections or other forward - looking statements regarding future events or the future financial performance of the Company . Actual events or results may differ materially from those in the projections or other forward - looking |
|
| September 11, 2017 |
As filed with the Securities and Exchange Commission on September 11, 2017 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on September 11, 2017 Registration No. |
|
| September 8, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 5, 2017 IMMUNE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or other jurisdiction of incorporation) (Com |
|
| August 29, 2017 |
Immune Pharmaceuticals Receives NASDAQ Letter Exhibit 99.1 Immune Pharmaceuticals Receives NASDAQ Letter NEW YORK, August 29, 2017 - Immune Pharmaceuticals Inc. (NASDAQ: IMNP) ("Immune") announced today that on August 23, 2017, the Company received written notice from the Listing Qualifications Department of The NASDAQ Stock Market LLC ("Nasdaq") that the Company no longer complies with the minimum stockholders' equity requirement under NASDA |
|
| August 29, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 23, 2017 IMMUNE PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or other jurisdiction of incorporation) (Commi |
|
| August 24, 2017 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of August [ ] 2017, between Immune Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively, the ?Purchasers?). WHEREAS, subject to the terms and con |
|
| August 24, 2017 |
Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIS |
|
| August 24, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 24, 2017 IMMUNE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or other jurisdiction of incorporation) (Commis |
|
| August 21, 2017 |
IMNP / Immune Pharmaceuticals Inc. FORM 10-Q (Quarterly Report) 10-Q 1 v47363610q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-36602 Immune Pharmaceuticals I |
|
| August 18, 2017 |
Exhibit 10.1 August 14, 2017 Anthony Fiorino, M.D., Ph.D. 550 Sylvan Avenue Englewood Cliffs, NJ 07632 Dear Tony, The purpose of this letter is to provide you with an employment offer specifying the terms and conditions of your employment with Immune Pharmaceuticals Inc. (the ?Company?). 1. Position and Duties You will function as the Chief Medical Officer and Chief Operating Officer of the Compan |
|
| August 18, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2017 IMMUNE PHARMACEUTICALS INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-36602 52-1841431 (State or other jurisdiction of incorporation or organ |
|
| August 14, 2017 |
Immune Pharmaceuticals NT 10-Q NT 10-Q 1 v473292nt10q.htm NT 10-Q OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE OMB Number: 3235-0058 COMMISSION Expires: October 31, 2018 Washington, D.C. 20549 Estimated average burden hours per response: 2.50 FORM 12b-25 SEC FILE NUMBER NOTIFICATION OF LATE FILING 001-36602 CUSIP NUMBER 45254C101 (Check one): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form |
|
| August 1, 2017 |
Immune Pharmaceuticals FORM S-1/A S-1/A 1 v472111s1a.htm FORM S-1/A As filed with the Securities and Exchange Commission on August 1, 2017 Registration No. 333-219094 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IMMUNE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 2836 52-1841431 (St |
|
| August 1, 2017 |
CORRESP 1 filename1.htm August 1, 2017 Dorrie Yale Division of Corporation Finance Office of Healthcare & Insurance Securities and Exchange Commission 100 F. Street, NE Washington, DC 20549 Re: Immune Pharmaceuticals Inc. Amendment No. 2 to Registration Statement on Form S-1 Filed July 28, 2017 File No. 333-219094 Dear Ms. Yale: This letter sets forth the responses of Immune Pharmaceuticals, Inc., |
|
| August 1, 2017 |
Immune Pharmaceuticals Inc. 550 Sylvan Avenue Englewood Cliffs, NJ 07632 August 1, 2017 VIA EDGAR Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Immune Pharmaceuticals Inc. Registration Statement on Form S-1 File No. 333-219094 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Se |
|
| July 28, 2017 |
S-1/A 1 v471770s1a.htm S-1/A As filed with the Securities and Exchange Commission on July 28, 2017 Registration No. 333-219094 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to form s-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IMMUNE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 2836 52-1841431 (State or |
|
| July 28, 2017 |
CORRESP 1 filename1.htm July 28, 2017 Dorrie Yale Division of Corporation Finance Office of Healthcare & Insurance Securities and Exchange Commission 100 F. Street, NE Washington, DC 20549 Re: Immune Pharmaceuticals Inc. Amendment No. 1 to Registration Statement on Form S-1 Filed July 18, 2017 File No. 333-219094 Dear Ms. Yale: This letter sets forth the responses of Immune Pharmaceuticals, Inc., |
|
| July 18, 2017 |
S-1/A 1 v470961s1a.htm S-1/A As filed with the Securities and Exchange Commission on July 18, 2017 Registration No. 333-219094 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to form s-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IMMUNE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 2836 52-1841431 (State or |
|
| July 18, 2017 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2017 IMMUNE PHARMACEUTICALS INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-36602 52-1841431 (State or other jurisdiction of incorporation or organiz |
|
| July 18, 2017 |
July 18, 2017 Dorrie Yale Division of Corporation Finance Office of Healthcare & Insurance Securities and Exchange Commission 100 F. |
|
| July 12, 2017 |
Exhibit 99.1 Cytovia Inc, Immune Pharmaceuticals? Oncology Subsidiary, Enters into a Definitive Agreement with Pint Pharma for the Licensing and Commercialization of Ceplene? in Latin America NEW YORK, July 11, 2017 /BusinessWire/ ? Cytovia Inc. (?Cytovia?) the oncology subsidiary of Immune Pharmaceuticals Inc. (NASDAQ: IMNP) ("Immune") announced today that it has entered into a licensing agreemen |
|
| July 12, 2017 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events 8-K 1 v4706838k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2017 IMMUNE PHARMACEUTICALS INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-36602 52-1841431 (State or other jurisdictio |
|
| July 12, 2017 |
Exhibit 10.1 LICENSE AND COMMERCIALIZATION AGREEMENT THIS LICENSE AND COMMERCIALIZATION AGREEMENT (the ?Agreement?) is entered into as of the signature date of the contract (the ?Effective Date?) by and between: CYTOVIA Inc, a subsidiary of IMMUNE Pharmaceuticals Inc, and a Delaware based company registered under number 330787805 with a business address at WeWork Tower 49, 12 East 49th Street, New |
|
| July 10, 2017 |
Exhibit 10.2 EXECUTION VERSION EXCHANGE AGREEMENT THIS EXCHANGE AGREEMENT (the ?Agreement?) is dated this 7th day of July, 2017 (the ?Effective Date?), by and among Immune Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and MEF I, L.P. (the ?Holder?). WHEREAS, the Holder entered into that certain Assignment Agreement, dated as of even date herewith (the ?Assignment Agreement?), by a |
|
| July 10, 2017 |
Exhibit 10.1 EXECUTION VERSION ASSIGNMENT AGREEMENT This Assignment Agreement (the ?Assignment Agreement?) is dated as of July 7, 2017 (the ?Effective Date?) by and among Immune Pharmaceuticals, Inc., a Delaware corporation (?IMNP?), Immune Pharmaceuticals USA Corp. (?IMNP USA?; and together with IMNP and each of their respective subsidiaries, ?Borrower?), MEF I, L.P. (?Assignee?), and Hercules Ca |
|
| July 10, 2017 |
EX-10.3 4 v470553ex10-3.htm EXHIBIT 10.3 Exhibit 10.3 EXECUTION VERSION NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY N |
|
| July 10, 2017 |
8-K 1 v4705538k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2017 IMMUNE PHARMACEUTICALS INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-36602 52-1841431 (State or other jurisdiction |
|
| June 30, 2017 |
Registration No.333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 form s-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IMMUNE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 2836 52-1841431 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employ |
|
| June 28, 2017 |
INAN / InterNatural Pharmaceuticals, Inc. / Skidmore Brian - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 0)* Immune Pharmaceuticals Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45254C200 (CUSIP Number) April 18, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| June 21, 2017 |
Exhibit 10.2 STANDBY FINANCING AGREEMENT This STANDBY FINANCING AGREEMENT, dated as of June 14, 2017 (the “Agreement”), by and between IMMUNE PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), on the one hand, and DANIEL KAZADO, an individual residing at Raanana, Israel (“Kazado” or the “Standby Financer”). WHEREAS, the Company intends to enter into an Asset Purchase Agreement, dated a |
|
| June 21, 2017 |
EX-10.1 2 v469408ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 Confidential June 15, 2017 MEDA PHARMA SARL - and - IMMUNE PHARMACEUTICALS, INC. ASSET PURCHASE AGREEMENT Concerning Ceplene and Certain Related Assets Project Ceplene APA (Execution Version) Page 1 of 70 Confidential Contents Clause Page 1. Interpretation 5 2. Sale and Purchase of the Assets 14 3. Purchase Price 14 4. VAT 16 5. Completion 16 6 |
|
| June 21, 2017 |
Immune Pharmaceuticals Signs Agreement to Regain Worldwide Rights for Ceplene EX-99.1 4 v469408ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Immune Pharmaceuticals Signs Agreement to Regain Worldwide Rights for Ceplene Immune’s subsidiary, Cytovia, plans commercialization activities in Europe and Latin America NEW YORK, June 15, 2017 /PRNewswire/ — Immune Pharmaceuticals Inc. (NASDAQ: IMNP) (‘Immune’) announced today that it has signed an agreement with Meda, a Mylan NV company (‘My |
|
| June 21, 2017 |
Immune Pharmaceuticals FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2017 IMMUNE PHARMACEUTICALS INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-36602 52-1841431 (State or other jurisdiction of incorporation or organiz |
|
| June 21, 2017 |
Immune Receives NASDAQ Compliance Letter EX-99.1 2 v469366ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Immune Receives NASDAQ Compliance Letter NEW YORK, June 19, 2017 /PRNewswire/ -Immune Pharmaceuticals Inc. (NASDAQ: IMNP) (the "Company”) announced today that on June 15, 2017, the Company received written notice from the Nasdaq that the Company has regained compliance with Listing Rule 5250(c)(1) and is in compliance with other applicable requ |
|
| June 21, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2017 IMMUNE PHARMACEUTICALS INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36602 52-1841431 (State or other jurisdiction of incorporation) (Commission F |
|
| June 14, 2017 |
IMNP / Immune Pharmaceuticals Inc. FORM 10-Q (Quarterly Report) 10-Q 1 v46847910q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-36602 Immune Pharmaceuticals |
|
| June 12, 2017 |
8-K 1 v4688338k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2017 IMMUNE PHARMACEUTICALS INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-36602 52-1841431 (State or other jurisdiction |
|
| May 26, 2017 |
Immune Pharmaceuticals 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2017 IMMUNE PHARMACEUTICALS INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36602 52-1841431 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 26, 2017 |
Immune Receives Nasdaq Letters Exhibit 99.1 Immune Receives Nasdaq Letters May 26, 2017 NEW YORK, May 26, 2017 /PRNewswire/ - Immune Pharmaceuticals Inc. (NASDAQ: IMNP) (the "Company”) announced today that on May 24, 2017, the Company received written notice from Nasdaq that the Company has regained compliance with the minimum bid price rule, as required by a decision of the Nasdaq Hearings Panel (the “Panel”) dated March 10, 2 |
|
| May 17, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2016 ¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 001-36602 Immune Pharmaceutical |
|
| May 17, 2017 |
Subsidiaries of Immune Pharmaceuticals Inc. Exhibit 21.1 Subsidiaries of Immune Pharmaceuticals Inc. The following are the subsidiaries of Immune Pharmaceuticals Inc.: Name Jurisdiction of Incorporation Immune Pharmaceuticals USA Corp. Delaware Immune Pharmaceuticals Ltd. Israel Maxim Pharmaceuticals, Inc. Delaware Cytovia, Inc. Delaware Immune Oncology Pharmaceuticals Inc. Delaware EpiCept GmbH (closed January 2015) Germany |
|
| May 16, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 10, 2017 IMMUNE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or other jurisdiction of incorpo |
|
| May 16, 2017 |
Exhibit 10.1 IMMUNE PHARMACEUTICALS INC. May 10, 2017 Mr. Elliot Maza 550 Sylvan Avenue Englewood Cliffs, NJ 07632 Dear Elliot: You have agreed to serve as interim Chief Executive Officer (“Interim CEO”) of Immune Pharmaceuticals Inc. (the “Company”) during the Company’s search for a successor Chief Executive Officer. On behalf of the Company, I am pleased to provide you with this letter agreement |
|
| May 16, 2017 |
Immune Pharmaceuticals NT 10-Q OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE OMB Number: 3235-0058 COMMISSION Expires: October 31, 2018 Washington, D. |
|
| May 15, 2017 |
Immune Pharmaceuticals 8-K/A (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 15, 2017 (May 4, 2017) IMMUNE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or other jurisdict |
|
| May 15, 2017 |
ORIGINAL ISSUE DISCOUNT CONVERTIBLE DEBENTURE Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIS |
|
| May 10, 2017 |
ORIGINAL ISSUE DISCOUNT CONVERTIBLE DEBENTURE Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIS |
|
| May 10, 2017 |
Immune Pharmaceuticals Announces Private Placement of up to $3.4 Million EX-99.1 4 v466527ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Immune Pharmaceuticals Announces Private Placement of up to $3.4 Million NEW YORK, May 4, 2017 /PRNewswire/ - Immune Pharmaceuticals Inc. (Nasdaq: IMNP) ("Immune" or the "Company") today announced that it has entered into definitive agreements with several institutional investors for a private placement of up to $3.4 million of convertible debe |
|
| May 10, 2017 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 4, 2017, between Immune Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditi |
|
| May 10, 2017 |
Immune Pharmaceuticals FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 4, 2017 IMMUNE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or other jurisdiction of incorporation) (Commission |
|
| April 27, 2017 |
Immune Pharmaceuticals Announces Corporate Restructuring Exhibit 99.1 Immune Pharmaceuticals Announces Corporate Restructuring - Inflammatory disease and dermatology business to become the focus of Immune Pharmaceuticals, Inc., with specific emphasis on bertilimumab and NanoCyclo products - Oncology business to be conducted within Immune's oncology subsidiary, Cytovia, Inc., under the leadership of Dr. Daniel Teper, with plans for possible spin-off of C |
|
| April 27, 2017 |
EX-10.1 2 v465438ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 Separation Agreement and Release of Claims This Separation Agreement and Release of Claims (this “Agreement”) is entered into by and between Daniel Teper (“Employee”) and Immune Pharmaceuticals Inc. (the “Company” or “Immune”), who together are referred to as the “Parties”, as of the 21st. day of April, 2017. Whereas, Employee’s employment with |
|
| April 27, 2017 |
8-K 1 v4654388k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 21, 2017 IMMUNE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or other jurisdicti |
|
| April 24, 2017 |
8-K 1 v4649558k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 18, 2017 IMMUNE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or other jurisdicti |
|
| April 24, 2017 |
EX-99.1 2 v464955ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Immune Receives Nasdaq Letter NEW YORK, April 24, 2017 /PRNewswire/ - Immune Pharmaceuticals Inc. (NASDAQ: IMNP) ("Immune") announced that on April 18, 2017 the Company has received written notice from the Listing Qualifications Department of The NASDAQ Stock Market LLC (“Nasdaq”) notifying that the Company does not comply with Nasdaq’s filing |
|
| April 19, 2017 |
Exhibit 3.1 I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF AMENDMENT OF ?IMMUNE PHARMACEUTICALS INC.?, FILED IN THIS OFFICE ON THE TWELFTH DAY OF APRIL, A.D. 2017, AT 1:47 O`CLOCK P.M. A FILED COPY OF THIS CERTIFICATE HAS BEEN FORWARDED TO THE KENT COUNTY RECORDER OF DEEDS. CERTIFICATE OF AMENDMENT |
|
| April 19, 2017 |
Immune Pharmaceuticals Announces 1-for-20 Reverse Stock Split Exhibit 99.1 Immune Pharmaceuticals Announces 1-for-20 Reverse Stock Split NEW YORK, April 12, 2017 /PRNewswire/ - Immune Pharmaceuticals Inc. (Nasdaq: IMNP) ("Immune" or the "Company"), today announced a reverse stock split of its shares of common stock at a ratio of 1-for-20. Beginning with the opening of trading on April 13, 2017, the Company?s common stock will continue to trade The Nasdaq Cap |
|
| April 19, 2017 |
Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this ?Agreement?) is made and entered into as of April 10, 2017, between IMMUNE PHARMACEUTICALS, INC., a Delaware corporation (the ?Company?) and each of the purchasers signatory hereto (each such purchaser, a ?Purchaser? and, collectively, the ?Purchasers?). This Agreement is made pursuant to the Securities Purchase Ag |
|
| April 19, 2017 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2017 IMMUNE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or other jurisdiction of incorporation) (Commiss |
|
| April 19, 2017 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this ?Agreement?), dated as of April 10, 2017, is entered into by and between IMMUNE PHARMACEUTICALS, INC., a Delaware corporation (the ?Company?), and EMA Financial, LLC, a Delaware limited liability company (the ?Purchaser?). WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to Sect |
|
| April 19, 2017 |
Exhibit 10.2 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR |
|
| April 19, 2017 |
Exhibit 10.4 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| March 31, 2017 |
Immune Pharmaceuticals NT 10-K NT 10-K 1 v463220nt10k.htm NT 10-K OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE OMB Number: 3235-0058 COMMISSION Expires: October 31, 2018 Washington, D.C. 20549 Estimated average burden hours per response: 2.50 FORM 12b-25 SEC FILE NUMBER NOTIFICATION OF LATE FILING 001-36602 CUSIP NUMBER 45254C101 (Check one): x Form 10-K o Form 20-F o Form 11-K o Form 10-Q o Form 10-D o Form N-SAR o Form |
|
| March 23, 2017 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 v4624678k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2017 IMMUNE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or other jurisdicti |
|
| March 23, 2017 |
Exhibit 10.1 COMMON STOCK PURCHASE AGREEMENT COMMON STOCK PURCHASE AGREEMENT (the “Agreement”), dated as of March 22, 2017 by and between IMMUNE PHARMACEUTICALS INC., a Delaware corporation (the “Company”), and HLHW IV, LLC, a Delaware limited liability company (the “Buyer”). Capitalized terms used herein and not otherwise defined herein are defined in Section 10 hereof. WHEREAS: Subject to the te |
|
| March 23, 2017 |
IMMUNE PHARMACEUTICALS INC. $1,600,000 of Common Stock 424B5 1 v462428424b5.htm 424B5 Prospectus Supplement Filed Pursuant to Rule 424(b)(5) (To Prospectus Dated October 28, 2014) Registration No. 333-198647 IMMUNE PHARMACEUTICALS INC. $1,600,000 of Common Stock This prospectus supplement relates to the issuance and sale of up to $1,600,000 of shares of our common stock, par value $0.001 per share (the “Common Stock”) pursuant to a Common Stock Purcha |
|
| March 22, 2017 |
IMMUNE PHARMACEUTICALS INC. $3,057,100 of Common Stock plus 1,150,835 Commitment Shares 424B5 1 v462427424b5.htm 424B5 Prospectus Supplement Filed Pursuant to Rule 424(b)(5) (To Prospectus Dated October 28, 2014) Registration No. 333-198647 IMMUNE PHARMACEUTICALS INC. $3,057,100 of Common Stock plus 1,150,835 Commitment Shares This prospectus supplement amends, supplements and supersedes our prospectus supplement dated February 3, 2017 and its accompanying prospectus dated October 28 |
|
| March 13, 2017 |
Financial Statements and Exhibits, Other Events 8-K 1 v4617248k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 13, 2017 IMMUNE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or other jurisdicti |
|
| March 13, 2017 |
Immune Pharmaceuticals Granted Additional Time to Comply with Nasdaq Listing Requirement EX-99.1 2 v461724ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Immune Pharmaceuticals Granted Additional Time to Comply with Nasdaq Listing Requirement NEW YORK, March 13, 2017 – Immune Pharmaceuticals Inc. (Nasdaq: IMNP) (“Immune” or the “Company”), announced today that following a hearing on March 9, 2017 , where the Company presented its plan to regain compliance including ongoing business events, the N |
|
| February 15, 2017 |
8-K 1 v4597848k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 9, 2017 IMMUNE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or other jurisdic |
|
| February 14, 2017 |
IMNP / Immune Pharmaceuticals Inc. / MMCAP International Inc. SPC Passive Investment SC 13G/A 1 mmcap-immune13ga2020817.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Amendment No. 2 INFORMATION STATEMENT PURSUANT TO RULES 13d-1 AND 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 IMMUNE PHARMACEUTICALS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 45254C101 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of This St |
|
| February 3, 2017 |
Exhibit 10.1 COMMON STOCK PURCHASE AGREEMENT COMMON STOCK PURCHASE AGREEMENT (the “Agreement”), dated as of February 3, 2017 by and between IMMUNE PHARMACEUTICALS INC., a Delaware corporation (the “Company”), and HLHW IV, LLC, a Delaware limited liability company (the “Buyer”). Capitalized terms used herein and not otherwise defined herein are defined in Section 10 hereof. WHEREAS: Subject to the |
|
| February 3, 2017 |
Immune Pharmaceuticals FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2017 IMMUNE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or other jurisdiction of incorporation) (Commi |
|
| February 3, 2017 |
IMMUNE PHARMACEUTICALS INC. $3,057,100 of Common Stock plus 1,150,835 Commitment Shares 424B5 1 v458373424b5.htm 424B5 Prospectus Supplement Filed Pursuant to Rule 424(b)(5) (To Prospectus Dated October 28, 2014) Registration No. 333-198647 IMMUNE PHARMACEUTICALS INC. $3,057,100 of Common Stock plus 1,150,835 Commitment Shares This prospectus supplement relates to the issuance and sale of up to $3,057,100 of shares of our common stock, par value $0.001 per share (the “Common Stock”) |
|
| February 1, 2017 |
EX-99.1 2 v458154ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Immune Pharmaceuticals Appoints New Chairman of the Board of Directors Ranch Kimball to Lead Immune's Board of Directors NEW YORK, Jan. 27, 2017 /PRNewswire/ - Immune Pharmaceuticals Inc. (Nasdaq: IMNP), announced today it has appointed Ranch C. Kimball, a highly regarded executive in healthcare, government, and private equity, as Chairman of i |
|
| February 1, 2017 |
8-K 1 v4581548k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 26, 2017 IMMUNE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or other jurisdic |
|
| January 31, 2017 |
IMMUNE PHARMACEUTICALS INC. 430 East 29th Street, Suite 940 New York, NY 10016 January 31, 2017 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Immune Pharmaceuticals Inc. Registration Statement on Form S-3, filed on December 2, 2016 (File No. 333-214873) Ladies and Gentlemen: Pursuant to Rule 477 promulgated under the Secu |
|
| January 19, 2017 |
8-K 1 v4571708k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 17, 2017 IMMUNE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or other jurisdic |
|
| January 9, 2017 |
Exhibit 99.1 Immune Pharmaceuticals Will Request an Appeal to Regain Compliance with Nasdaq?s Minimum Bid Price Rule NEW YORK, Jan. 9, 2017 ? Immune Pharmaceuticals Inc. (Nasdaq: IMNP) (?Immune?), announced today that it intends to request a hearing before the Nasdaq Listing Qualifications Staff Panel to appeal a notification that Immune?s securities are subject to delisting from The Nasdaq Capita |
|
| January 9, 2017 |
Immune Pharmaceuticals FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 4, 2017 IMMUNE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or other jurisdiction of incorporation) (Commis |
|
| December 22, 2016 |
Entry into a Material Definitive Agreement 8-K 1 v4556668k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2016 IMMUNE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or other jurisdi |
|
| December 20, 2016 |
Submission of Matters to a Vote of Security Holders 8-K 1 v4554338k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2016 IMMUNE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or other jurisdi |
|
| December 15, 2016 |
8-K 1 v4551078k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2016 IMMUNE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or other jurisdi |
|
| December 2, 2016 |
As filed with the Securities and Exchange Commission on December 1, 2016 Registration No. |
|
| November 22, 2016 |
8-K 1 v4535468k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2016 IMMUNE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or other jurisdi |
|
| November 22, 2016 |
Exhibit 10.4 COMMON STOCK PURCHASE AGREEMENT COMMON STOCK PURCHASE AGREEMENT (the ?Agreement?), dated as of November 17, 2016 by and between IMMUNE PHARMACEUTICALS INC., a Delaware corporation (the ?Company?), and HLHW IV, LLC, a Delaware limited liability company (the ?Buyer?). Capitalized terms used herein and not otherwise defined herein are defined in Section 10 hereof. WHEREAS: Subject to the |
|
| November 22, 2016 |
Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this ?Agreement?) is made as of November 17, 2016, among Immune Pharmaceuticals Inc., a Delaware corporation (the ?Company?), and each signatory hereto (each, an ?Investor? and collectively, the ?Investors?). Capitalized terms not otherwise defined herein shall have the meaning ascribed to them in the Purchase Agreement |
|
| November 22, 2016 |
EX-10.2 4 v453546ex10-2.htm EXHIBIT 10.2 Exhibit 10.2 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) |
|
| November 22, 2016 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of November 17, 2016, between Immune Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and the purchasers identified on the signature pages hereto (each, including its successors and assigns, the ?Purchasers? and each a ?Purchaser?). WHEREAS, subject to the terms and conditions |
|
| November 22, 2016 |
424B5 1 v453559424b5.htm FORM 424(B)(5) Prospectus Supplement Filed Pursuant to Rule 424(b)(5) (To Prospectus Dated October 28, 2014) Registration No. 333-198647 IMMUNE PHARMACEUTICALS INC. $6,706,789 of Common Stock plus 3,684,211 Commitment Shares and 1,610,526 Loan Shares This prospectus supplement relates to the issuance and sale of up to $6,706,789 of shares of our common stock, par value $0. |
|
| November 18, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-36602 IMMUNE PHARMACEUTICALS INC. (Exact name of registra |
|
| November 15, 2016 |
Immune Pharmaceuticals NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC File Number 001-37370 NOTIFICATION OF LATE FILING (Check One): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: September 30, 2016 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form |
|
| November 8, 2016 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2016 IMMUNE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or other jurisdiction of incorporation) (Commi |
|
| November 2, 2016 |
Immune Pharmaceuticals DEF 14A DEF 14A 1 v451908def14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as pe |
|
| October 21, 2016 |
Immune Pharmaceuticals FORM PRE 14A PRE 14A 1 v450854pre14a.htm FORM PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only ( |
|
| September 16, 2016 |
Immune Pharmaceuticals FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2016 IMMUNE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or other jurisdiction of incorporation) (Com |
|
| September 16, 2016 |
EX-10.1 2 v448942ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 BINDING AGREEMENT Immune Pharmaceuticals Inc. ("Immune") and Novel Pain Therapeutics, LLC (“NPT” and, together with Immune, the “Parties”) entered into an option agreement on May 15, 2016 followed by an amendment on July 15, 2016 regarding the development and commercialization of Amiket. The parties now agree that NPT or its designees shall pur |
|
| September 16, 2016 |
Exhibit 99.1 Immune Pharmaceuticals Signs Agreement to Fund Maxim Pharmaceuticals, Inc., its Pain and Neurology subsidiary NEW YORK, September 16, 2016 /PRNewswire/ - Immune Pharmaceuticals Inc. (NASDAQ: IMNP) ("Immune" or the ?Company?), a biopharmaceutical company focused on the development of targeted therapeutics for the treatment of inflammatory diseases and cancer, announced today that the B |
|
| September 7, 2016 |
Exhibit 10.1 STOCK PURCHASE AGREEMENT This Stock Purchase Agreement (?Agreement?) is made and entered into on September 6, 2016 (?Effective Date?), by and between Immune Pharmaceuticals Inc., a Delaware corporation (?Company?), and the investor whose name appears on the signature page hereto (?Investor?). Recitals A. The parties desire that, upon the terms and subject to the conditions herein, Inv |
|
| September 7, 2016 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 v4483478k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2016 IMMUNE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or other jurisdi |
|
| September 7, 2016 |
IMMUNE PHARMACEUTICALS INC. 4,000,000 Shares of Common Stock 424B5 1 v448356424b5.htm 424B5 Prospectus Supplement Filed Pursuant to Rule 424(b)(5) (To Prospectus Dated October 28, 2014) Registration No. 333-198647 IMMUNE PHARMACEUTICALS INC. 4,000,000 Shares of Common Stock We are offering up to 4,000,000 shares of our common stock to institutional investors pursuant to this prospectus supplement and the accompanying prospectus and a stock purchase agreemen |
|
| August 18, 2016 |
Exhibit 99.1 Immune Pharmaceuticals Provides Business and R&D Update and Announces Second Quarter 2016 Financial Results NEW YORK, August 16, 2016/PRNewswire/- Immune Pharmaceuticals Inc. (NASDAQ:IMNP) (?Immune? or the ?Company?) announced financial results for the second quarter and six months ended June 30, 2016 as well as provided pipeline highlights and a business update. ?Immune has continued |
|
| August 18, 2016 |
8-K 1 v4472628k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2016 (August 16, 2016) IMMUNE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State |
|
| August 18, 2016 |
Exhibit 99.1 Immune Pharmaceuticals Provides Business and R&D Update and Announces Second Quarter 2016 Financial Results NEW YORK, August 16, 2016/PRNewswire/- Immune Pharmaceuticals Inc. (NASDAQ:IMNP) (?Immune? or the ?Company?) announced financial results for the second quarter and six months ended June 30, 2016 as well as provided pipeline highlights and a business update. ?Immune has continued |
|
| August 18, 2016 |
8-K 1 v4472628k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2016 (August 16, 2016) IMMUNE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State |
|
| August 15, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-36602 IMMUNE PHARMACEUTICALS INC. (Exact name of registrant as |
|
| August 15, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-36602 IMMUNE PHARMACEUTICALS INC. (Exact name of registrant as |
|
| August 3, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2016 IMMUNE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or other jurisdiction of incorporation) (Commissi |
|
| August 3, 2016 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 29, 2016, between Immune Pharmaceuticals Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and condit |
|
| August 3, 2016 |
Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| July 29, 2016 |
IMMUNE PHARMACEUTICALS INC. 3,174,603 Shares of Common Stock Prospectus Supplement Filed Pursuant to Rule 424(b)(5) (To Prospectus Dated October 28, 2014) Registration No. |
|
| July 19, 2016 |
Exhibit 10.1 PROMISSORY NOTE New York, NY U.S.A U.S. $,000.00 , 2016 FOR VALUE RECEIVED, the undersigned, Immune Pharmaceuticals, Inc., a Delaware corporation located at 430 East 29th Street, Suite 940, New York, NY 10016 (?Immune?) promises to pay to the order of (?Lender?), the principal sum of Thousand United States dollars (US $,000.00). Interest Rate: Interest shall accrue on the outstanding |
|
| July 19, 2016 |
8-K 1 v4445378k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2016 (July 15, 2016) IMMUNE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or o |
|
| July 19, 2016 |
EX-99.1 3 v444542ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 IMMUNE Pharmaceuticals to Form Pain and Neurology Spin Off Company around AmiKet IMMUNE and NPT targets closing date of September 15, 2016. New York, July 19, 2016 - Immune Pharmaceuticals Inc. (NASDAQ: IMNP) (“Immune”), a biopharmaceutical company focused on the development of targeted therapeutics for the treatment of inflammatory diseases an |
|
| July 19, 2016 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events 8-K 1 v4445428k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2016 (July 18, 2016) IMMUNE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or o |
|
| July 19, 2016 |
EX-10.1 2 v444542ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 AMENDMENT NO. 1 TO LICENSE OPTION AGREEMENT This Amendment No. 1 to the License Option Agreement (the "Agreement") made and entered into as of the 18th day of July 2016, between Immune Pharmaceuticals Inc., a Delaware corporation (“Immune”) and Novel Pain Therapeutics, LLC., a New York limited liability company (“NPT”), both referred to hereina |
|
| July 6, 2016 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 6, 2016 IMMUNE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or other jurisdiction of incorporation) (Commissio |
|
| July 1, 2016 |
EX-99.1 2 v443446ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Immune Pharmaceuticals Inc. and Subsidiaries Pro forma Condensed Consolidated Balance Sheets ($ in thousands, except share and per share amounts) As Reported Pro forma Adjustments Pro forma March 31, 2016 Conversion of 247 Series D Preferred Stock Sale of 6.0 million shares of common stock under the Capital Access Agreements Costs Related to Ca |
|
| July 1, 2016 |
Financial Statements and Exhibits, Other Events 8-K 1 v4434468k.htm FORM 8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2016 IMMUNE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or other jurisdiction |
|
| June 13, 2016 |
EX-10.1 2 v442143ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 AMENDMENT NO. 1 TO CAPITAL ACCESS AGREEMENT This Amendment No. 1 to the Capital Access Agreement dated June 10, 2016 (this “Amendment”), between Immune Pharmaceuticals Inc., a Delaware corporation having its principal place of business at 430 East 29th Street, Suite 940, New York, NY 10016 (“Immune”), and Regatta Select Healthcare LLC, a Delawa |
|
| June 13, 2016 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 v4421438k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2016 IMMUNE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or other jurisdictio |
|
| June 13, 2016 |
EX-10.2 3 v442143ex10-2.htm EXHIBIT 10.2 Exhibit 10.2 EXECUTION COPY CAPITAL ACCESS AGREEMENT This CAPITAL ACCESS AGREEMENT (the “Agreement”), is dated as of June 10, 2016, by and between Immune Pharmaceuticals Inc., a Delaware corporation, (the “Company”), and Regatta Select Healthcare, LLC, a Delaware limited liability company (including any designee(s) thereof, the “Investor”). WHEREAS: Subject |
|
| June 13, 2016 |
IMMUNE PHARMACEUTICALS INC. Up to 3,700,000 Shares of Common Stock Prospectus Supplement Filed Pursuant to Rule 424(b)(5) (To Prospectus Dated October 28, 2014) Registration No. |
|
| June 13, 2016 |
IMMUNE PHARMACEUTICALS INC. Common Stock Prospectus Supplement Filed Pursuant to Rule 424(b)(5) (To Prospectus Dated October 28, 2014) Registration No. |
|
| May 16, 2016 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 v4400258k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2016 IMMUNE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or other jurisdiction of i |
|
| May 16, 2016 |
Exhibit 99.1 Immune Pharmaceuticals Provides Business and R&D Update and Announces First Quarter 2016 Financial Results NEW YORK, May 16, 2016 /PRNewswire/ - Immune Pharmaceuticals Inc. (NASDAQ:IMNP) (?Immune? or the ?Company?) announced financial results for the first quarter ended March 31, 2016. Business and Research & Development (?R&D?) Update Immune continues to pursue its strategy to unlock |
|
| May 16, 2016 |
Exhibit 10.3 License Option Agreement This Agreement made this day of May 15, 2016 by and between Immune Pharmaceuticals Inc. (“Immune”) with a principal place of business at 430 East 29th Street, Suite 940, New York, NY 10016 and Novel Pain Therapeutics LLC (“NPT”), a newly formed limited liability company with an office at 52 East End Avenue #12A New York, NY 10028 Whereas Immune has intellectua |
|
| May 16, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 000-51290 Immune Pharmaceuticals Inc. (Exact name of registrant a |
|
| April 29, 2016 |
Immune Pharmaceuticals 10-K/A (Annual Report) 10-K/A 1 v43837810ka.htm 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) x Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2015 ¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to |
|
| April 20, 2016 |
IMMUNE PHARMACEUTICALS INC. Up to 3,500,000 Shares of Common Stock 424B5 1 v437309424b5.htm 424B5 Prospectus Supplement Filed Pursuant to Rule 424(b)(5) (To Prospectus Dated October 28, 2014) Registration No. 333-198647 IMMUNE PHARMACEUTICALS INC. Up to 3,500,000 Shares of Common Stock This prospectus supplement relates to the issuance and sale of up to 3,500,000 shares of our common stock pursuant to a capital access agreement, or the Capital Access Agreement, t |
|
| April 20, 2016 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2016 IMMUNE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or other jurisdiction of incorporation) (Commiss |
|
| April 20, 2016 |
EX-10.1 3 v437306ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 EXECUTION COPY CAPITAL ACCESS AGREEMENT This CAPITAL ACCESS AGREEMENT (the “Agreement”), is dated as of April 19, 2016, by and between Immune Pharmaceuticals Inc., a Delaware corporation, (the “Company”), and Regatta Select Healthcare, LLC, a Delaware limited liability company (including any designee(s) thereof, the “Investor”). WHEREAS: Subjec |
|
| March 31, 2016 |
Exhibit 99.1 Immune Pharmaceuticals Provides Business Update and Announces Fourth Quarter and Full Year 2015 Financial Results NEW YORK, March 30, 2016 /PRNewswire/ - Immune Pharmaceuticals Inc. (NASDAQ:IMNP) (?Immune? or the ?Company?) announced financial results for the fourth quarter and full year ended December 31, 2015. Immune filed its Annual Report on Form 10-K for fiscal year 2015 on March |
|
| March 31, 2016 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2016 IMMUNE PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 001-36602 52-1841431 (State or other jurisdiction of incorporation) (Commiss |
|
| March 30, 2016 |
EX-10.45 3 v434974ex10-45.htm EXHIBIT 10.45 Exhibit 10.45 November 2, 2015 To: Monica Luchi 293 St. David Court Mount Laurel, NJ 08054 Dear Monica, The purpose of this letter is to provide you with an employment offer specifying the terms and conditions of your employment with Immune Pharmaceuticals Inc. as follows: 1. Position and Duties: You will function as the Executive Vice President and Chie |
|
| March 30, 2016 |
EX-10.44 2 v434974ex10-44.htm EXHIBIT 10.44 Exhibit 10.44 |
|
| March 30, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2015 ¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 000-51290 Immune Pharmaceutical |
|
| March 30, 2016 |
Subsidiaries of Immune Pharmaceuticals Inc. Exhibit 21.1 Subsidiaries of Immune Pharmaceuticals Inc. The following are the subsidiaries of Immune Pharmaceuticals Inc.: Name Jurisdiction of Incorporation Immune Pharmaceuticals USA Corp. Delaware Immune Pharmaceuticals Ltd. Israel Maxim Pharmaceuticals, Inc. Delaware Cytovia, Inc. Delaware EpiCept GmbH (closed January 2015) Germany |
|
| March 1, 2016 |
Exhibit 24 POWER OF ATTORNEY Know all by these present, that the undersigned hereby constitutes and appoints each of Daniel G. |
